Barrons
06 Oct 2026, 11:38 UTC · 1h ago
This Glass Maker's Stock Is Rising 19% on Monster Quarter and Guidance Boost
Impact · against what's priced in
The earnings beat and guidance boost for Apogee Enterprises are immaterial to the stock price. The current valuation is driven entirely by a pending acquisition at $135.11 per share, making standalone operational performance irrelevant unless the deal fails.
- APGE+0.00
Doesn't touch the price's assumptions
- The price assumes
The all-cash acquisition of Apogee by AbbVie at $135.11 per share
The stock is trading at the acquisition price of $135.11; standalone fiscal 2027 guidance and quarterly earnings do not change the fixed cash payout the market is already expecting from the AbbVie deal.
What APGE's price assumes · Sep 24
Top 1 mover · tap to explore
